Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company is focused on the development of its lead product candidate Ygalo®(melphalan flufenamide), the first alkylating peptide belonging to the novel class of Peptidase Enhanced Compounds (PEnCs). Ygalo has an unique MOA. Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma.